Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

PCIG, a web-based application to explore immune-genomics interactions across cancer types

  • Pedrola Gómez, Anna|||0000-0002-0490-3851
  • Franch-Expósito, Sebastià|||0000-0002-4542-1701
  • Lahoz, Sara|||0000-0002-4491-9911
  • Esteban-Fabró, Roger
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Camps Polo, Jordi|||0000-0003-2929-4228
Genomic alterations can modulate the tumor immunophenotype depending on their nature and tissue of origin. Although this immune-genomic interaction may shape disease progression and response to immunotherapy, the factors governing such dynamics and the influence of each tissue-specific context remain poorly understood. Here, we have developed the PanCancer ImmunoGenomics (PCIG) tool, a web-based resource that provides researchers with the opportunity to mine immunome-genome relationships across several cancer types using data from the Pan-Cancer Analysis of Whole-Genomes (PCAWG) study, which comprises.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Copy-number intratumor heterogeneity increases the risk of relapse in chemotherapy-naive stage colon cancer

  • Lahoz, Sara|||0000-0002-4491-9911
  • Archilla, Ivan|||0000-0002-2142-0608
  • Asensio, Elena
  • Hernández-Illán, Eva
  • Ferrer Menduiña, Queralt|||0000-0003-3177-4618
  • López-Prades, Sandra|||0000-0001-8208-2959
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Rey Azpiri, Javier del|||0000-0001-7887-7871
  • Sanz-Pamplona, Rebeca
  • Lozano, Juan José
  • Castells, Antoni|||0000-0001-8431-2033
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Camps Polo, Jordi|||0000-0003-2929-4228
Optimal selection of high-risk patients with stage II colon cancer is crucial to ensure clinical benefit of adjuvant chemotherapy. Here, we investigated the prognostic value of genomic intratumor heterogeneity and aneuploidy for disease recurrence. We combined targeted sequencing, SNP arrays, fluorescence in situ hybridization, and immunohistochemistry on a retrospective cohort of 84 untreated stage II colon cancer patients. We assessed the clonality of copy-number alterations (CNAs) and mutations, CD8 + lymphocyte infiltration, and their association with time to recurrence. Prognostic factors were included in machine learning analysis to evaluate their ability to predict individual relapse risk. Tumors from recurrent patients displayed a greater proportion of CNAs compared with non-recurrent (mean 31.3% versus 23%, respectively; p = 0.014). Furthermore, patients with elevated tumor CNA load exhibited a higher risk of recurrence compared with those with low levels [ p = 0.038; hazard ratio (HR) 2.46], which was confirmed in an independent cohort (p = 0.004; HR 3.82). Candidate chromosome-specific aberrations frequently observed in recurrent cases included gain of the chromosome arm 13q (p = 0.02; HR 2.67) and loss of heterozygosity at 17q22-q24.3 (p = 0.05; HR 2.69). CNA load positively correlated with intratumor heterogeneity (R = 0.52; p < 0.0001). Consistently, incremental subclonal CNAs were associated with an elevated risk of relapse (p = 0.028; HR 2.20), which we did not observe for subclonal single-nucleotide variants and small insertions and deletions. The clinico-genomic model rated an area under the curve of 0.83, achieving a 10% incremental gain compared with clinicopathological markers (p = 0.047). In conclusion, tumor aneuploidy and copy-number intratumor heterogeneity were predictive of poor outcome and improved discriminative performance in early-stage colon cancer. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cytology Smears, An Enhanced Alternative Method for Colorectal Cancer pN Stage-A Multicentre Study

  • Diaz-Mercedes, Sherley|||0000-0002-8164-8639
  • Archilla, Ivan|||0000-0002-2142-0608
  • Lahoz, Sara|||0000-0002-4491-9911
  • Rodrigo Calvo, María Teresa|||0000-0001-6675-3425
  • López-Prades, Sandra|||0000-0001-8208-2959
  • Tarragona, Jordi|||0000-0002-1459-4087
  • Landolfi, Stefania|||0000-0002-1059-635X
  • Concha, Angel
  • Machado, Isidro|||0000-0001-7318-1330
  • Maurel, Joan|||0000-0002-9413-5592
  • Chic, Nuria
  • Castells, Antoni|||0000-0001-8431-2033
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Camps Polo, Jordi|||0000-0003-2929-4228
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
Recurrence of stage II (pT3-T4 pN0) colorectal cancer (CRC) occurs in about 15% of patients and it is often due to undetected lymph node (LN) metastases with conventional pathology haematoxylin and eosin (H&E) LN analysis. Despite more sensitive molecular methods of LN staging having proved to have prognostic value in stage II CRC, we aimed at determining whether the pN stage could be better assessed with LN cytology smears. We analysed 3936 LNs from 217 CRC surgical resections, using three methods, H&E, cytology smears, and the One Step Nucleic Acid Amplification (OSNA) molecular assay. We compared the pN stages obtained from both H&E and cytology, as well as with the OSNA results. We concluded that LN analysis with cytology smears not only enables performing the pN stage, but detects more LN metastases than H&E, with a similar detection rate to molecular methods. Cytology LN analysis would allow a better patient therapeutic management. Stage II colorectal cancer (CRC) recurrence remains a clinical problem. Some of these patients are true stage III CRC with a pN0 pathology stage. This large prospective multicentre cohort study aimed at evaluating the diagnostic ability of lymph node (LN) cytology smears to perform the pN stage and compare it with the conventional haematoxylin and eosin (H&E) pathology pN stage. Additionally, we used the One-Step Nucleic Acid Amplification (OSNA), a high-sensitive molecular method of LN staging. A total of 3936 fresh LNs from 217 CRC surgical specimens were examined by three methods, H&E, LN cytology smears, and OSNA. H&E detected 29% of patients with positive LNs, cytology smears 35%, and OSNA 33.2% (p < 0.0001). H&E and cytology concordantly classified 92.2% of tumours, and 88.5% between OSNA and H&E. Cytology had 96.8% sensitivity and 90.3% specificity to discriminate positive/negative patients compared to H&E (p = 0.004), and 87.3% sensitivity and 89% specificity when compared to OSNA (p = 0.56). Patients with positive LNs detected by any of the three methods had significantly worse disease-free and overall survival. We conclude that pN stage accuracy for detecting positive LNs is superior with LN cytological smears than with conventional H&E, which would enable a better pN stage and management of early-stage CRC patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53 -Mutated Metastatic Colorectal Cancer

  • Lahoz, Sara|||0000-0002-4491-9911
  • Rodríguez, Adela|||0000-0002-4899-6607
  • Fernández Barat, Laia|||0000-0001-7528-9636
  • Gorría, Teresa
  • Moreno, Reinaldo
  • Esposito, Francis|||0000-0002-5028-9637
  • Oliveres, Helena|||0000-0003-1801-1181
  • Albiol, Santiago
  • Saurí Nadal, Tamara|||0000-0002-7479-5120
  • Pesantez, David|||0000-0003-0257-8538
  • Riu-Viladoms, G.|||0000-0002-8259-0811
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Jares, Pedro
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Pineda, Estela|||0000-0003-2128-747X
  • Castells, Antoni|||0000-0001-8431-2033
  • Prat, Aleix|||0000-0003-2377-540X
  • Maurel, Joan|||0000-0002-9413-5592
  • Camps Polo, Jordi|||0000-0003-2929-4228
The mutational status of certain genes can be useful to advance therapeutic decision making and clinical management of cancer patients. In metastatic colorectal cancer, current clinicopathological factors employed in clinical practice have low or modest individual effect on survival, leading to a poor ability to discriminate patients at high risk. Here, we obtained data from metastatic colorectal cancer patients undergoing molecular testing by targeted gene sequencing, and we identified SMAD4 and FBXW7 mutated genes as negative prognostic markers in TP53 -driven tumors, which also improved the predictive performance to discriminate high-risk patients beyond clinical factors alone. This negative prognostic impact of co-occurring SMAD4 / TP53 and FBXW7 / TP53 mutations was confirmed in an independent validation analysis using publicly available data. Next-generation sequencing (NGS) provides a molecular rationale to inform prognostic stratification and to guide personalized treatment in cancer patients. Here, we determined the prognostic and predictive value of actionable mutated genes in metastatic colorectal cancer (mCRC). Among a total of 294 mCRC tumors examined by targeted NGS, 200 of them derived from patients treated with first-line chemotherapy plus/minus monoclonal antibodies were included in prognostic analyses. Discriminative performance was assessed by time-dependent estimates of the area under the curve (AUC). The most recurrently mutated genes were TP53 (64%), KRAS or NRAS (49%), PIK3CA (15%), SMAD4 (14%), BRAF (13%), and FBXW7 (9.5%). Mutations in FBXW7 correlated with worse OS rates (p = 0.036; HR, 2.24) independently of clinical factors. Concurrent mutations in TP53 and FBXW7 were associated with increased risk of death (p = 0.02; HR, 3.31) as well as double-mutated TP53 and SMAD4 (p = 0.03; HR, 2.91). Analysis of the MSK-IMPACT mCRC cohort (N = 1095 patients) confirmed the same prognostic trend for the previously identified mutated genes. Addition of the mutational status of these genes upon clinical factors resulted in a time-dependent AUC of 87%. Gene set enrichment analysis revealed specific molecular pathways associated with SMAD4 and FBXW7 mutations in TP53 -defficient tumors. Conclusively, SMAD4 and FBXW7 mutations in TP53 -altered tumors were predictive of a negative prognostic outcome in mCRC patients treated with first-line regimens.